CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-08 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-07-20 | Martell Bridget A Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-07-20 | Nielsen Jack Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-07-20 | Hirth Peter Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-07-20 | Scopa James Paul Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-07-20 | Nuechterlein Carole Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-03-15 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-03-15 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +78,750 | 78,750 | ||
| 2023-03-15 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +78,750 | 78,750 | ||
| 2023-03-15 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +78,750 | 78,750 | ||
| 2023-03-15 | Beigelman Leonid President | Grant or award · Stock Option (Right to Buy) | +169,500 | 169,500 | ||
| 2023-03-15 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +242,500 | 242,500 | ||
| 2022-07-07 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +46,000 | 46,000 | ||
| 2022-07-07 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +52,500 | 52,500 | ||
| 2022-07-07 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +52,500 | 52,500 | ||
| 2022-07-07 | Beigelman Leonid President | Grant or award · Stock Option (Right to Buy) | +113,000 | 113,000 | ||
| 2022-07-07 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +161,700 | 161,700 | ||
| 2022-07-07 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2022-06-23 | Woiwode Thomas Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-06-23 | Hirth Peter Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 |
Page 5 of 12 · 238 trades